All In Biotech

Drug Trial Radar · NCT03051009

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

A Multi-Centre Trial Investigating the Long Term Safety and Tolerability of Desmopressin (FE 992026) Orally Disintegrating Tablets for the Treatment of Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Last checked: Nov 19, 2026Latest source record: Sep 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 503 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

503

Actual

Start

Jan 11, 2017

Primary completion

Sep 11, 2018

Study completion Sep 11, 2018

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Demonstrate the safety and tolerability of desmopressin ODT during long-term treatment of subjects with nocturia due to nocturnal polyuria, for up to 1 year

Conditions

  • Nocturia

Interventions

  • Desmopressin ODT 25 μgDrug

  • Desmopressin ODT 50 μgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency and severity of adverse eventsTime frame: Up to 1 year
  2. Clinically significant changes in laboratory values and vital signsTime frame: Up to 1 year
  3. The incidence and severity of hyponatraemiaTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site (there may be other sites in this country)

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.